ArticleInternational journal of environmental research and public health2019
Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Article in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.International journal of environmental research and public health · 2020Trial
- Prognostic Factors After the First Recurrence of Ovarian Cancer.Journal of clinical medicine · 2025Article
- Molecular mechanisms of cisplatin resistance in ovarian cancer.Genes & diseases · 2024Review
- Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.Cancers · 2021Review
- Application of hyaluronic acid in patients with interstitial cystitis.Journal of the Chinese Medical Association : JCMA · 2021Article
- Collision carcinoma of endometrial adenocarcinoma and primary serous fallopian tube carcinoma: a case report.The Journal of international medical research · 2020Article
- Does any serum marker predict the ovarian endometrioma accompanied with or without deep infiltrative endometriosis?Journal of the Chinese Medical Association : JCMA · 2020Article
- Functional Gene Clusters in Global Pathogenesis of Clear Cell Carcinoma of the Ovary Discovered by Integrated Analysis of Transcriptomes.International journal of environmental research and public health · 2020Article
- Immunology and ovarian cancers.Journal of the Chinese Medical Association : JCMA · 2020Review
- Painless surgery and long-term quality of life.Journal of the Chinese Medical Association : JCMA · 2020Article
- Aberrant sialylation in ovarian cancers.Journal of the Chinese Medical Association : JCMA · 2020Review
- Does a simple hematological examination predict the response and side effects in patients undergoing induction chemotherapy and/or neoadjuvant chemotherapy?Journal of the Chinese Medical Association : JCMA · 2020Article
- Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study.Clinical epidemiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A combination of cytoreductive surgery, either primary (PCS) or interval (ICS), and chemotherapy with a platinum-paclitaxel regimen is the well-accepted treatment for advanced-stage epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), and primary peritoneal serous carcinoma (PPSC), but it is still uncertain whether a combination of dose-dense weekly paclitaxel and low-dose triweekly cisplatin is useful in the management of these patients. Therefore, we retrospectively evaluated the outcomes of women with advanced-stage EOC, FTC, and PPSC treated with PCS and subsequent dose-dense weekly paclitaxel (80 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.